Crescent Biopharma (CBIO) Cash from Investing Activities (2013 - 2026)

Crescent Biopharma (CBIO) has reported Cash from Investing Activities for 14 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Investing Activities rose 1355.0% year-over-year to $1.8 million; the TTM figure through Jun 2026 stood at -$79.2 million (down 56449.29% YoY), while the FY2025 annual figure was -$72.9 million, down 364185.28% from the prior year.
• Cash from Investing Activities grew to $1.8 million in Q2 2026 per CBIO's latest filing, from -$8.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $1.8 million in Q2 2026 and bottomed at -$72.2 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$5.3 million across 5 years, with a median of -$7866.0 in 2023.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 80000.0% — and 2026, when it surged 1355.0%.
• Crescent Biopharma's Cash from Investing Activities stood at -$1.0 in 2022, then tumbled by 80000.0% to -$801.0 in 2023, then plunged by 216.23% to -$2533.0 in 2024, then slumped by 2849998.7% to -$72.2 million in 2025, then surged by 102.43% to $1.8 million in 2026.
• Business Quant data shows CBIO's Cash from Investing Activities at $1.8 million in Q2 2026, -$8.1 million in Q1 2026, and -$72.2 million in Q4 2025.